Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oncolytic virus and application

A technology of oncolytic virus and Newcastle disease virus, applied in the biological field, to achieve the effect of promoting virus-specific immune response, enhancing anti-tumor effect, and precisely targeting tumor anti-tumor effect

Active Publication Date: 2018-11-06
DALIAN MEDICAL UNIVERSITY
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Newcastle disease virus can spread the cytotoxic virus to every cancer cell in the body through viral replication, but the immune system's production of virus-neutralizing antibodies may limit this possibility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oncolytic virus and application
  • Oncolytic virus and application
  • Oncolytic virus and application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0038] The carrier loaded with oncolytic virus can enhance the oncolytic ability of the carrier and improve the anti-tumor effect of the carrier on the basis of the tumor-targeting ability. The embodiment of the present invention also provides a preparation method of immune effector cells loaded with oncolytic virus, the preparation method comprising the following steps:

[0039] The preparation method includes contacting an oncolytic virus solution with an immune effector cell solution, and the oncolytic virus in the oncolytic virus solution is the oncolytic virus NDV / FMW provided in the above-mentioned embodiments of the present invention.

[0040] Further, the multiplicity of infection of the oncolytic virus is 10-100 MOI, and the cell density of the immune effector cell solution is 1ⅹ10 6 ~5ⅹ10 6 cells / mL.

[0041] The multiplicity of infection of the oncolytic virus can be: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 , 52, 54, 56,...

no. 1 example

[0048] This example provides a method for preparing immune effector cells (CIK cells) loaded with oncolytic virus.

[0049] Induction and proliferation of CIK cells

[0050] Experimental consumables

[0051] X-VIVO 15 serum-free medium: 1000mL / bottle, produced by Lonza, Walkersville, MD, USA; IL-2 (recombinant human interleukin-2): 200,000 IU / bottle and 1 million IU / bottle, produced The business is Shandong Quangang Pharmaceutical Co., Ltd.; IL-1α (recombinant human interleukin-1α): 10 μg / cartridge, the manufacturer is PEPROTECH; CD3 antibody (anti-CD3 monoclonal antibody): 500 μg / cartridge, the manufacturer is e- Bioscience; IFN-γ (recombinant human IFN-γ): 1.0mg / bottle, the manufacturer is PEPROTECH.

[0052] experimental method

[0053] First, experiment preparation, ultraviolet disinfection for 30 minutes. Turn on the exhaust and lighting switches of the ultra-clean workbench, and wipe the workbench with 75% alcohol.

[0054] Collect blood for routine examination of p...

no. 2 example

[0066] Verify that the immune effector cells prepared by the preparation method of the first embodiment are loaded with oncolytic virus.

[0067] experimental method

[0068] The immune effector cells CIK cells loaded with oncolytic virus provided in the first embodiment were observed with a laser confocal microscope. Specifically, put cell slides in a six-well plate, inoculate CIK cell suspension (2mL / well), put it in an incubator for pre-culture for 24 hours, and infect CIK cells with 10MOI oncolytic virus (NDV / FMW) at 37°C 4 hours.

[0069] Take out slides, wash twice with PBS, 5 minutes each time; fix with 4% paraformaldehyde for 15 minutes, wash twice with PBS, 5 minutes each time; permeabilize with 0.03% Triton 100 for 10 minutes, wash twice with PBS, 5 minutes each time Minutes; HN (NDV virus protein) antibody incubated overnight at 4°C, washed twice with PBS, 5 minutes each; goat anti-rabbit red fluorescent secondary antibody incubated at room temperature for 30 minu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an oncolytic virus and an application thereof, and relates to the biotechnology field. The preservation number of the oncolytic virus is CCTCC No. V201809. The oncolytic virushas an anti-tumor effect and can be used for preparing an anti-tumor drug with the excellent anti-tumor effect.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to an oncolytic virus and its application. Background technique [0002] Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. In the early stage, some tumor cells are specifically infected and destroyed by oncolytic viruses. Subsequently, oncolytic viruses replicate and multiply in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert oncolytic effects by directly lysing tumor cells or stimulating the host to generate an anti-tumor immune response. The potential of viruses with antitumor drugs was discovered in the early 20th century, but it was not formally studied and developed until the 1960s. [0003] At present, a variety of viruses including adenovirus, reovirus, measles virus, herpes simplex virus, Newcastle disease virus and vaccinia virus have been tested clinically as o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/00C12N15/86A61K35/768A61P35/00C12R1/93
CPCA61K35/768A61P35/00C12N7/00C12N15/86C12N2760/18121C12N2760/18143
Inventor 孟松树姜珂
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com